Positive Results Announced from a Phase III Trial of Fingolimod in Children and Adolescents with MS

A study in children and adolescents with MS showed that treatment with oral fingolimod (Gilenya®, Novartis) significantly reduced the number of relapses over a period of up to two years, compared to treatment with interferon beta-1a, according to a press release from Novartis. The full results will be presented at the ECTRIMS-ACTRIMS meeting in October in Paris, France. Fingolimod is not currently approved for the treatment of pediatric MS. Novartis plans to analyze these data and present the results to regulatory authorities. Although MS occurs most commonly in adults, it…

Favicon of www.nationalmssociety.org da : www.nationalmssociety.org

Prosegui la lettura...
Traduci l'articolo...

Sclerosi Multipla News

Potrebbe interessarti anche

Argomenti correlati